7/31/2019 IB Final Copy

1/37

MMS SEM-3

7/31/2019 IB Final Copy

2/37

RANBAXYA

Presentation on

Largest pharmaceutical company out of India

with global reach and competencies across the value chain

7/31/2019 IB Final Copy

3/37

CONTENTS

INTRODUCTION MISSION &VALUES

GLOBAL PRESENCE

JOURNEY

MODE OF ENTRY THE GLOBAL GENERICS ADVANTAGES

COMPETITIVE ADVANTAGES

RESEARCH & DEVELOPMENT

GLOBAL MANUFACTURING STRENGTH

DEVELOPED MARKET PRESENCE

EMERGING MARKET PRESENCE

CORPORATE SOCIAL RESPONSIBILITY

7/31/2019 IB Final Copy

4/37

INTRODUCTION

7/31/2019 IB Final Copy

5/37

Founded in 1961

Ranbaxy was started by Ranbir Singh and Gurbax Singh in

1937 as a distributor for a Japanese company Shionogi

India's largest pharmaceutical companies , Ranbaxy & Daiichi

Sankyo combined rank among the top 20 global

pharmaceutical companies

Worldwide Presence - Ground presence in 46 countries, products sold in over

125 countries

Manufacturing locations in 8 countries

7/31/2019 IB Final Copy

6/37

Highest R&D spender amongst Indian Pharmaceutical

companiesBusiness

International 77%

Domestic 23%

Around 14000 employees globally represented by 50

nationalities

One of the largest distribution networks that comprises over

4000 field force Project 'Viraat' - A key initiative to strengthen company's

domestic leadership position

7/31/2019 IB Final Copy

7/37

MISSION

&VALUES

7/31/2019 IB Final Copy

8/37

MISSIONEnriching lives globally, with quality and affordable

pharmaceuticals

VALUES

Achieving customer satisfaction is fundamental to our business

Provide products and services of the highest quality

Practice dignity and equity in relationships and provide

opportunities for our people to realize their full potential

Ensure profitable growth and enhance wealth of the shareholders

Foster mutually beneficial relations with all our business partners Manage our operations with high concern for safety and

environment

Be a responsible corporate citizen

7/31/2019 IB Final Copy

9/37

GLOBAL PRESENCE

7/31/2019 IB Final Copy

10/37

7/31/2019 IB Final Copy

11/37

7/31/2019 IB Final Copy

12/37

North America &

Japan

Europe

Other Emerging

Markets

BRICS

No. 1 in India

Large, reputed player inCIS; growing rapidly

No. 6 in Brazil

No. 5 in S. Africa

43/54 countries in Africa

Latam & Asia Pacific:long standing presence;good understanding;robust businesses

Pioneer entrant from

India Strong local presence

Canada: New market,growing rapidly

Well established

23/25 EU markets

No. 1 Generic player inRomania

http://images.google.com/imgres?imgurl=http://www.molsci.csiro.au/library/gifs/compass.gif&imgrefurl=http://www.molsci.csiro.au/library/compass.html&h=344&w=333&sz=5&hl=en&start=5&um=1&usg=__sF-kZKyOnm_27RqfytHy2J4-u9Q=&tbnid=bojfNRH6EAixTM:&tbnh=120&tbnw=116&prev=/images?q=compass+image&um=1&hl=en&rlz=1T4GGLG_en___IN298&sa=Nhttp://images.google.com/imgres?imgurl=http://www.molsci.csiro.au/library/gifs/compass.gif&imgrefurl=http://www.molsci.csiro.au/library/compass.html&h=344&w=333&sz=5&hl=en&start=5&um=1&usg=__sF-kZKyOnm_27RqfytHy2J4-u9Q=&tbnid=bojfNRH6EAixTM:&tbnh=120&tbnw=116&prev=/images?q=compass+image&um=1&hl=en&rlz=1T4GGLG_en___IN298&sa=N

7/31/2019 IB Final Copy

13/37

In June 2008, Daiichi-Sankyo acquired a 34.8% stake inRanbaxy, for a value $2.4 billion

In November 2008, Daiichi-Sankyo completed the takeover of

the company from the founding Singh family in a deal worth

$4.6 billion

by acquiring a 63.92% stake in Ranbaxy

Significant and sustained operational and strategic synergies

across the globe

Combining innovator and generics capabilities, to straddle full

spectrum of pharma value chain

7/31/2019 IB Final Copy

14/37

HEADQUARTERS

LOCATED AT GURGAON, NEW DELHI

7/31/2019 IB Final Copy

15/37

JOURNEY

7/31/2019 IB Final Copy

16/37

7/31/2019 IB Final Copy

17/37

MODE OF ENTRY

7/31/2019 IB Final Copy

18/37

Foreign Direct Investment(FDI)

Joint Venture

Acquisition

Licensing

7/31/2019 IB Final Copy

19/37

STRATEGY

7/31/2019 IB Final Copy

20/37

Follows a geocentric approach

It is the Companys constant endeavour to provide a wide

basket of generic and innovator products, leveraging the

unique Hybrid Business Model with Daiichi Sankyo

7/31/2019 IB Final Copy

21/37

BUSINESS MODEL

7/31/2019 IB Final Copy

22/37

THE GLOBAL GENERICSADVANTAGES

7/31/2019 IB Final Copy

23/37

7/31/2019 IB Final Copy

24/37

COMPETITIVE ADVANTAGES

7/31/2019 IB Final Copy

25/37

7/31/2019 IB Final Copy

26/37

RESEARCH & DEVELOPMENT

7/31/2019 IB Final Copy

27/37

Dedicated Facilities for Innovative & Generics Research

More than 1200 R&D Personnel

Highest R&D spender amongst Indian Pharmaceutical

companies

NDDS based products (4 platform technologies)

NDDR - Arterolane + PQP (Anti malaria)

One program with GSK (Respiratory)

Collaboration in Clinical Development of NCE

7/31/2019 IB Final Copy

28/37

GLOBAL MANUFACTURINGSTRENGTH

7/31/2019 IB Final Copy

29/37

7 manufacturing locations worldwide

API facilities - increasing vertical integration

Creating capacities for specialty products

New facilities added in cost advantageous geographies

7/31/2019 IB Final Copy

30/37

USA IRELAND ROMANIA

INDIA SOUTH AFRICA MALAYSIA

NIGERIA

7/31/2019 IB Final Copy

31/37

DEVELOPED MARKETPRESENCE

7/31/2019 IB Final Copy

32/37

USA Largest generic market worldwide

Significant patent expiries through 2015

EUROPEAN UNION

Germany, UK - mature markets

France, Spain, Italy, Romania - emerging markets

Ranbaxy has presence in 23 of the 27 EU countries

JAPAN

Emerging generic market

Opportunity to develop, manufacture & supply products through

Daiichi Sankyo

7/31/2019 IB Final Copy

33/37

EMERGING MARKET PRESENCE

7/31/2019 IB Final Copy

34/37

INDIA Among India's largest pharmaceutical companies

Growing at a fast pace

ROMANIA

Ranked as the No. 1 Generics Company

Strategic for servicing EU operations

RUSSIA & UKRAINE

Strong base in acute therapies

Fast expanding into chronic and OTC segments

SOUTH AFRICA

Key market in the African continent

A stron No. 5 la er in the re ion

7/31/2019 IB Final Copy

35/37

Corporate social

responsibility

7/31/2019 IB Final Copy

36/37

7/31/2019 IB Final Copy

37/37